$86.39
0.580.68%
Ult. Agg.: Oct 29, 4:00 PM
Mirum Pharmaceuticals (MIRM) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Mirum Pharmaceuticals (MIRM) ha pubblicato l'ultima guidance il agosto 5, 2026 per fiscal year 2026. La società ha previsto un fatturato pari a $680M - $700M per il periodo.
Rispetto alle previsioni precedenti, Mirum Pharmaceuticals ha modificato le sue previsioni di fatturato da un intervallo precedente di .
Mirum Pharmaceuticals ha pubblicato {{revenueDirection}} aggiornamenti delle previsioni tra il {{revenuePriorRange}} e il Mirum Pharmaceuticals. 13
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.80 | $-0.36 | $0.04 | $-0.14 |
| Actual | $-0.80 | $-0.50 | $-0.12 | $0.05 |
| Surprise | 0.00% | -38.9% | -400.0% | +135.7% |
| Revenue | ||||
| Estimate | $165.5M | $148.2M | $141.6M | $131.1M |
| Actual | $176.2M | $159.9M | $148.9M | $133.0M |
| Surprise | +6.46% | +7.91% | +5.19% | +1.49% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.44 | $-0.47 | $-0.17 | $-0.16 |
| Revenue | ||||
| Consensus | $177.7M | $182.9M | — | — |
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $-0.80 | $-0.80 | 0.00 % |
| Q1 | May 6, 2026 | $-0.50 | $-0.36 | -38.9 % |
| Q4 | Feb 25, 2026 | $-0.12 | $0.04 | -400.0 % |
| Q3 | Nov 4, 2025 | $0.05 | $-0.14 | 135.7 % |
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $176.24M | $165.55M | 6.46 % |
| Q1 | May 6, 2026 | $159.88M | $148.17M | 7.91 % |
| Q4 | Feb 25, 2026 | $148.93M | $141.58M | 5.19 % |
| Q3 | Nov 4, 2025 | $133.01M | $131.06M | 1.49 % |